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Abstract
Introduction: The Mirena intrauterine system has been licensed as a contraceptive in the United
Kingdom since May 1995. The use of an intrauterine system as a primary method of contraception
among women has been slowly increasing over the last few years and they now account for about
3% of contraceptive use in England. The Mirena intrauterine system now also has a license for the
management of idiopathic menorrhagia. Women may be informed that the rate of uterine
perforation associated with intrauterine contraceptive use is low (0-2.3 per 1000 insertions). The
rate of perforation reported with the Mirena intrauterine system in a large observational cohort
study was 0.9 per 1000 insertions.
Case presentation: In this case report, the diagnosis of an intraperitoneal Mirena intrauterine
system was noted nearly four years after its insertion, despite the patient having had a vaginal
hysterectomy and admissions to hospital in the interim with complaints of abdominal pain.
Conclusion:  This case report demonstrates clearly that whenever there is a question of a
intrauterine system having fallen out following an ultrasound scan report showing an empty uterus,
clinicians should also perform an abdominal X-ray.
Introduction
The Mirena intrauterine system (IUS) has been licensed as
a contraceptive in the United Kingdom since May 1995.
Recent data from the Information Centre for Health and
Social Care, NHS Contraceptive Services in England sug-
gest that the use of an IUS as a primary method of contra-
ception among women has been slowly increasing over
the last few years and now accounts for about 3% of con-
traceptive use [1].
The Mirena IUS now also has a licence for the manage-
ment of idiopathic menorrhagia [2] and may therefore be
used by women who do not require contraception. Uter-
ine perforation is a serious, albeit rare, complication in
using an intrauterine device. Women may be informed,
however, that the rate of uterine perforation associated
with intrauterine contraceptive use is low (0-2.3 per 1000
insertions) [3-7]. The rate of perforation reported with the
Mirena IUS in a large observational cohort study was 0.9
per 1000 insertions [8].
In this case report, the diagnosis of an intraperitoneal
Mirena IUS was noted nearly four years after its insertion,
despite the patient having had a vaginal hysterectomy and
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admissions to hospital in the interim. This case report
demonstrates clearly that whenever there is a question of
the IUS having fallen out following an ultrasound scan
report showing an empty uterus, clinicians should per-
form an abdominal X-ray [3].
Case presentation
A 33-year-old British Caucasian woman, para 2, with a
long standing history of menorrhagia, dysmenorrhoea
and tiredness was referred by her general practitioner (GP)
to the hospital in 2002. Her GP had treated for anaemia
and tiredness. Her periods had been regular although in
the previous few months she had bled continuously. Her
periods had become heavy after tubal sterilisation in
1996. Cervical cytology had always been normal. In the
past she was diagnosed with duodenal ulcer in 1996,
underwent a laparoscopy for pelvic pain for suspected
endometriosis in 1997 and had an appendicectomy in
1997. On investigation she was anaemic with low iron
and ferritin levels. Pelvic ultrasound scan was normal. For
management of her menorrhagia, she opted for Micro-
wave Endometrial Ablation which was performed in
August 2002. Upon review after four months, she com-
plained of erratic bleeding but no pain. An ultrasound
scan showed irregular endometrium. The patient was
booked for hysteroscopy under general anaesthesia. The
procedure was attempted in September 2003 and was
abandoned due to difficulties passing the hysteroscope
through the endocervical canal. The hysteroscopy was
repeated in January 2004 and a few intrauterine adhesions
were reported. An endometrial biopsy was done just
before the insertion of a Mirena IUS under the same gen-
eral anaesthetic. The results of the biopsy were normal. It
was not recorded if the sitting of the IUS was checked post
insertion hysteroscopically. Her GP was asked to check the
threads in four to six weeks time.
A month later, she was admitted to the hospital with right
upper quadrant pain and a problematic bleeding pattern.
Ultrasound at this stage showed a normal size uterus but
the Mirena IUS was not in situ. It was assumed the Mirena
IUS had fallen out. The patient elected to have a vaginal
hysterectomy to solve her bleeding problems, which was
performed in September 2005.
In January 2007, she was admitted to the hospital with
right upper quadrant pain again and all investigations
including chest X-ray, abdominal ultrasound scan and
blood tests were normal. She had an upper GI endoscopy,
which showed a gastric ulcer.
She was admitted again in April 2008 with pelvic pain. An
abdominal X-ray showed the lost IUS (Figure 1) and a CT
scan showed the IUS lying anteriorly under the rectus
muscles and adjacent to the dome of the bladder. In April
2008 the IUS was retrieved laparoscopically. The omen-
tum was adherent to the anterior abdominal wall and the
Mirena IUS was found in the omentum, (Figure 2). The
IUS was removed easily from the abdominal cavity lapar-
oscopically. The right tube and ovary were adherent to the
right pelvic wall and they were freed up. The procedure
was uneventful and the patient was discharged the same
day. The most likely cause of the abdominal pain in this
Abdominal X-ray with the Mirena IUS (arrowed) Figure 1
Abdominal X-ray with the Mirena IUS (arrowed).
The Mirena intrauterine system (circled) within the omen- tum Figure 2
The Mirena intrauterine system (circled) within the 
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patient was the adhesions. The patient had no complaints
of abdominal pain in the 6 months of follow-up.
Discussion
Uterine perforation is a serious, albeit rare, complication
of intrauterine contraceptive use. The rate of perforation
reported with the Mirena IUS in a large observational
cohort study was 0.9 per 1000 insertions [8]. However,
the UK Medical Eligibility Criteria for Contraceptive use
[9] considers a uterine cavity distorted for any reason, con-
genital or acquired, to be a category 4 condition, i.e. a con-
dition which represents an unacceptable health risk if the
contraceptive method is used. The British National For-
mulary (BNF) [10] also suggests that intrauterine devices
(IUDs) should be used with caution in severely scarred
uteri. In this case, the Mirena was inserted after intrauter-
ine surgery. The Faculty of Sexual and Reproductive
Healthcare, Clinical Guidance 2007, 'Intrauterine Contra-
ception' [3] recommends that a routine follow-up visit
should be done after the first menses following insertion
of intrauterine contraception or three to six weeks after the
insertion. The Royal College of Obstetricians and Gynae-
cologists recommends [11] that women who present with
persistent menorrhagia, despite Mirena IUS use, should
be advised to return for further assessment of the uterine
cavity, using hysteroscopy or ultrasound scan, to exclude
pathology. An endometrial biopsy should be considered
in all women with persistent menorrhagia who are 35 or
older, because progesterone therapy may alter endome-
trial histology and may mask a premalignant or malignant
lesion.
Endometrial ablation or resection are surgical methods to
manage menorrhagia. Intrauterine scarring may occur fol-
lowing treatment. A narrative review paper on treatment
after hysteroscopic surgery suggests that an acceptable
post-operative method of contraception after endometrial
ablation is the Mirena IUS, as it protects the endometrium
and there is a high rate of amenorrhoea [12]. However,
following successful endometrial ablation the uterine cav-
ity is usually severely narrowed making insertion of an
IUS impossible and it would not normally be considered
in these circumstances. Significant bleeding would suggest
failure of the procedure, and if IUS was to be considered
it should only be done with hysteroscopic assistance by an
experienced gynaecologist [13]. A thorough literature
search of the Medline, Embase and Cochrane databases
did not reveal any similar case reports and also did not
report any formal guidance to the use of the Mirena IUS
device following endometrial microwave ablation. There
was one article, though, regarding insertion of Mirena
IUS, after endometrial resection [14].
Generally, the presence of risk factors should always be
identified before the insertion of IUDs. Risk factors
include the postpartum period or during breast feeding, a
retroverted uterus, uterine anomalies and inexperience of
the operators which can increase the risk of perforation
[15].
In summary, in this case report, the diagnosis of the
Mirena IUS inside the peritoneal cavity was noted nearly
four years after the insertion and was presumed to be due
to perforation or partial perforation of the uterus. The
patient had several admissions to hospital under the care
of gynaecologists or gastroenterologists complaining for
upper or lower abdominal pain. She even had a vaginal
hysterectomy. Had she undergone an abdominal hyster-
ectomy, the Mirena IUS may have been noted at that time.
This case report demonstrates the need for regular IUS
thread checks and that following an ultrasound report
showing an empty uterus in a symptomatic patient, an
abdominal X-ray should be performed to identify whether
or not the IUS is inside the peritoneal cavity. We advocate
that following basic rules after IUS insertion, such as hys-
teroscopic insertion post ablation, annual check-up of IUS
position, X-ray for a patient complaining of abdominal
pain will prevent complications or assist in their early
diagnosis.
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